esophageal cancer
Conditions
Interventions
Not applicable, retrospective study
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Inclusion criteria
Inclusion criteria: diagnosis of esophageal or esophageal junction cancer; completed esophageal or gastroesophageal resectioneligible for adjuvant nivolumab (i.e. received neo-adjuvant chemoradiation, surgical margin is microscopically negative for residual tumor, incomplete pathological response and no contra indications for immune therapy as considered by their treating physician)
Exclusion criteria
Exclusion criteria: Complete pathological response in resection specimenIrradical surgical resection marginsOther neoadjuvant treatment than neoadjuvant chemoradiotherapy (i.e. perioperative chemotherapy, definitive chemoradiotherapy) Contra-indications for immune therapy (e.g. auto-immune disorders, low performance status) leading to not starting adjuvant nivolumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the proportion of patients with locoregional and/or distant metastasis, as detected at baseline CT and at different time points during adjuvant Nivolumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes include the method of detection of disease recurrence | — |
Countries
Netherlands
Contacts
Public ContactT.J. Huizer
Erasmus Universiteit Rotterdam
Outcome results
None listed